Abstract
Angiotensin II type 1 receptor antagonists (AT1R blockers, or ARBs) are used commonly in the treatment of cardiovascular disorders such as heart failure and hypertension. Their clinical success arises from their ability to prevent deleterious Gαq protein activation downstream of AT1R, which leads to a decrease in morbidity and mortality. Recent studies have identified AT1R ligands that concurrently inhibit Gαq protein-dependent signaling and activate Gαq proteinindependent/ β-arrestin-dependent signaling downstream of AT1R, events that may actually improve cardiovascular performance more than conventional ARBs. The ability of such ligands to induce intracellular signaling events in an AT1R-β-arrestin-dependent manner while preventing AT1R-Gαq protein activity defines them as biased AT1R ligands. This mini-review will highlight recent studies that have defined biased signaling at the AT1R and discuss the possible clinical relevance of β-arrestin-biased AT1R ligands in the cardiovascular system.
Keywords: apoptosis, AT1R, β-arrestin, biased signaling, contractility, hypertrophy, internalization, transactivation, antagonists, cardiovascular disorders, hypertension, morbidity, mortality, cardiomyocytes, endocytosis
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Functional Relevance of Biased Signaling at the Angiotensin II Type 1 Receptor
Volume: 11 Issue: 2
Author(s): Douglas G. Tilley
Affiliation:
Keywords: apoptosis, AT1R, β-arrestin, biased signaling, contractility, hypertrophy, internalization, transactivation, antagonists, cardiovascular disorders, hypertension, morbidity, mortality, cardiomyocytes, endocytosis
Abstract: Angiotensin II type 1 receptor antagonists (AT1R blockers, or ARBs) are used commonly in the treatment of cardiovascular disorders such as heart failure and hypertension. Their clinical success arises from their ability to prevent deleterious Gαq protein activation downstream of AT1R, which leads to a decrease in morbidity and mortality. Recent studies have identified AT1R ligands that concurrently inhibit Gαq protein-dependent signaling and activate Gαq proteinindependent/ β-arrestin-dependent signaling downstream of AT1R, events that may actually improve cardiovascular performance more than conventional ARBs. The ability of such ligands to induce intracellular signaling events in an AT1R-β-arrestin-dependent manner while preventing AT1R-Gαq protein activity defines them as biased AT1R ligands. This mini-review will highlight recent studies that have defined biased signaling at the AT1R and discuss the possible clinical relevance of β-arrestin-biased AT1R ligands in the cardiovascular system.
Export Options
About this article
Cite this article as:
G. Tilley Douglas, Functional Relevance of Biased Signaling at the Angiotensin II Type 1 Receptor, Endocrine, Metabolic & Immune Disorders - Drug Targets 2011; 11 (2) . https://dx.doi.org/10.2174/187153011795564133
DOI https://dx.doi.org/10.2174/187153011795564133 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pituitary Dysfunction as a Cause of Cardiovascular Disease
Current Pharmaceutical Design Novel uses of Imaging in AF Ablation
Recent Patents on Cardiovascular Drug Discovery Peptide and Non-peptide Antagonists Targeting Endothelin Receptors in Physiology and Pathology
Current Pharmaceutical Design Ca2+ Signalling in Damaged Endothelium and Arterial Remodelling: Do Connexin Hemichannels Provide a Suitable Target to Prevent In-stent Restenosis?
Current Drug Therapy Rheumatoid Arthritis: An Autoimmune Disease with Female Preponderance and Cardiovascular Risk Equivalent to Diabetes Mellitus: Role of Cardiovascular Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued) Intracellular Calcium Homeostasis and Kidney Disease
Current Medicinal Chemistry Patent Selections
Recent Patents on Cardiovascular Drug Discovery Resistance to Anti-VEGF Agents
Current Pharmaceutical Design Interactions of Cisplatin with non-DNA Targets and their Influence on Anticancer Activity and Drug Toxicity: The Complex World of the Platinum Complex
Current Cancer Drug Targets Carotid Artery Stenting for the Prevention of Thromboembolic Stroke
Vascular Disease Prevention (Discontinued) The Beneficial Role of Vitamin D in Human Immunodeficiency Virus Infection
Current HIV Research Sphingolipids in Cell Signaling: Their Function as Receptor Ligands, Second Messengers, and Raft Constituents
Current Immunology Reviews (Discontinued) Systematic Reviews of Animal Experiments Demonstrate Poor Contributions Toward Human Healthcare
Reviews on Recent Clinical Trials A Systematic Approach to Hypertensive Urgencies and Emergencies
Current Hypertension Reviews New Technologies for the Diagnosis of Sleep Apnea
Current Hypertension Reviews Atypical Chest Pain in ACS: A Trap Especially for Women
Current Pharmaceutical Design Biological Activities of Receptor-interacting Protein 140 in Adipocytes and Metabolic Diseases
Current Diabetes Reviews Paclitaxel Formulations: Challenges and Novel Delivery Options
Current Drug Delivery In Vitro CYP2D Inhibitory Effect and Influence on Pharmacokinetics and Pharmacodynamic Parameters of Metoprolol Succinate by Terminalia arjuna in Rats
Drug Metabolism Letters Cooling the Injured Brain: How Does Moderate Hypothermia Influence the Pathophysiology of Traumatic Brain Injury
Current Pharmaceutical Design